Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Overhaul Of GMP Oversight Will Include Numerous Targeted Guidances

This article was originally published in The Pink Sheet Daily

Executive Summary

The initiative to develop risk-based oversight of drug manufacturing will enter a new, less frenetic phase at its two-year anniversary in August. The project is a carryover from Deputy Commissioner Crawford's first term as acting head of FDA.

You may also be interested in...



FDA Good Manufacturing Practices Initiative Report Slated For October

GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.

FDA Good Manufacturing Practices Initiative Report Slated For October

GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.

FDA Clinical Practices Oversight Will Move To Risk-Based Approach

The agency will begin reviewing how it regulates clinical trial research within a year, FDA Good Clinical Practice Director Lepay says at DIA annual meeting. Inspections will move from a "rote" approach towards a risk-based method modeled on the GMP risk management initiative.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel